A clinician's guide
KCNQ2- and KCNQ3-Associated Epilepsy
A practical summary of recognition, genotype–phenotype correlations, and treatment, drawn from the Cambridge Element.
For neonatologists, neurologists & geneticists
Recognize it early. Treat it right.
KCNQ2 is the most common cause of neonatal-onset epilepsy with encephalopathy. Its seizures have a distinctive electroclinical signature, and they respond best to sodium channel blockers, not the phenobarbital most newborns receive first.
Key points
Four things to know at the bedside
of genetically tested neonatal epilepsies with encephalopathy were KCNQ2-DEE in a multicenter cohort.
Typical seizure: asymmetric tonic posturing with apnea and desaturation, side varying between events.
Sodium channel blockers are first-line for loss-of-function variants, started at the earliest clinical suspicion.
Gain-of-function variants cause different syndromes; treat by seizure type, not by gene.
Recognizing KCNQ2/3 neonatal seizures
The electroclinical pattern can support a presumptive diagnosis, and treatment, before genetic results return. It differs clearly from acute provoked seizures.
| Feature | Acute provoked seizures | KCNQ2/3 neonatal-onset epilepsy |
|---|---|---|
| Duration | Often prolonged | Mostly short, 1–2 minutes |
| Semiology | Electrographic only, or clonic | Asymmetric tonic or tonic-sequential, with apnea and desaturation |
| Clinical onset | Frequent delay between electrographic and clinical onset | Clinical signs at seizure onset; electroclinical dissociation is rare |
| EEG | Focal, slowly evolving rhythm; no prolonged post-ictal depression | Diffuse attenuation, rapidly spreading fast activity, prolonged post-ictal suppression (visible on aEEG too) |
Adapted from Fig. 14, after Cornet et al., 2021.
The genotype–phenotype spectrum
Whether a variant reduces (loss-of-function) or increases (gain-of-function) M-current largely determines the clinical picture.
Loss-of-function (LoF)
Self-limited familial neonatal epilepsy (SLFNE)
- Onset most often days 2–4 of life; babies may present in the well-baby nursery or after discharge
- KCNQ2 in ~80% of families, KCNQ3 in ~5%; penetrance ~80%
- Normal exam between seizures and normal MRI
- Seizures usually resolve by 6 months (up to 12–15); later recurrence reported in up to 31%
KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)
- Usually de novo missense or in-frame indels in S4, pore, and C-terminal A/B helices
- Onset often in the first 24 hours; can be mistaken for HIE
- Encephalopathy, hypotonia, abnormal interictal EEG; MRI may show transient deep nuclear T2 change
- Outcomes range from mild to profound; seizures tend to ease over the first two decades
KCNQ3-DEE (biallelic)
- Very rare; reported with homozygous frameshift or compound heterozygous variants
- Neonatal-onset epilepsy with variable developmental severity, even among siblings
- Heterozygous truncating KCNQ3 variants have no established phenotype
Gain-of-function (GoF)
KCNQ2 R201C / R201H
Neonatal encephalopathy with non-epileptic, stimulus-triggered myoclonus, burst suppression, and central hypoventilation. Most later develop infantile spasms.
KCNQ2 R198Q
Infantile spasms with hypsarrhythmia at 4–5 months, without preceding neonatal seizures.
KCNQ2 R144
Global developmental delay and hypotonia without neonatal epilepsy; seizures in some.
KCNQ3 R230 (and R227)
Developmental delay in years 1–2, marked language impairment, autism features, and sleep-potentiated multifocal spikes.
Treatment
LoF variants (SLFNE and KCNQ2-DEE)
- First-line: a sodium channel blocker such as carbamazepine or oxcarbazepine. Many patients respond within hours of the first dose.
- Start early: time to CBZ correlated with length of hospitalization in a retrospective series.
- Phenobarbital is mostly ineffective in KCNQ2-DEE and not recommended there; levetiracetam and benzodiazepines also respond poorly.
- Caution: CBZ is contraindicated in epileptic spasms.
- Retigabine (ezogabine): mixed retrospective results; 5 of 9 KCNQ2-DEE patients improved, none became seizure-free.
GoF variants
- No established treatment recommendations; case series are small and responses vary.
- Choose medication by seizure type rather than gene-specific guidance.
- Vigabatrin helped spasms and myoclonus in some R201C/H patients, but not consistently.
- In KCNQ3 GoF, consider the burden of sleep-activated spikes; some respond to high-dose benzodiazepines.
New from Q2 Quick Notes: early sodium channel blocker use linked to better outcomes in people with loss-of-function KCNQ2 variants.
Read Quick Note #21
Emerging therapies
Biohaven Opakalim (formerly BHV-7000)
Kv7 activator with improved subtype selectivity and potency.
UpdateGenetic therapies
Gene editing and antisense oligonucleotides expected to be evaluated this decade.
Genetic counseling notes
- Heterozygous truncating KCNQ2 variants and KCNQ3 missense variants usually point to SLFNE; de novo KCNQ2 missense variants are harder to predict.
- With ~80% penetrance, parents may be unaffected or unaware of family history.
- Mosaic variants usually mean milder disease; parental germline mosaicism affects recurrence risk.
- Prognosis should state what is known and what is not, even for recurrent variants.
Treat patients with KCNQ2?
Join the directory families use to find you.
Source: Weckhuysen S, George AL Jr, eds. KCNQ2- and KCNQ3-Associated Epilepsy. Cambridge Elements: Genetics in Epilepsy. Cambridge University Press; 2022. doi:10.1017/9781009278270. Summarized and adapted under CC BY-NC 4.0.
This page is educational and does not replace clinical judgment.